Regenxbio Inc is a renowned biotechnology company specializing in the development of life-changing gene therapies for patients suffering from severe diseases. The company's core values revolve around innovation, scientific excellence, and patient-centric focus. Regenxbio Inc is dedicated to improving the lives of individuals by harnessing the power of gene therapy to address unmet medical needs. With a commitment to integrity, collaboration, and transparency, Regenxbio Inc strives to bring groundbreaking treatments to patients, build strong partnerships, and continuously push the boundaries of scientific discovery. Their corporate philosophy embodies a relentless pursuit of transformative therapies to revolutionize healthcare and provide hope for those in need.

Regenxbio Inc is primarily present in the United States.

Regenxbio Inc has achieved several significant milestones in its history. One notable milestone is the successful completion of a Phase I clinical trial for its lead product candidate, RGX-314. This novel gene therapy aims to treat wet age-related macular degeneration (AMD). Additionally, Regenxbio has entered into partnerships with renowned pharmaceutical companies, including Novartis and Audentes Therapeutics, to further expand its gene therapy platform. The company has also garnered regulatory approvals for its gene therapy products, including FDA breakthrough therapy designation for RGX-314. These achievements highlight Regenxbio's commitment to developing innovative gene therapies for various genetic disorders, including eye diseases.

Regenxbio Inc. is a biotechnology company focused on the development and commercialization of gene therapy treatments. Founded in 2008, Regenxbio has grown into a leading player in the field of gene therapy, with a strong emphasis on adeno-associated virus (AAV) vector technology. The company has developed a proprietary NAV Technology Platform, which enables the precise and targeted delivery of therapeutic genes to specific cells in the body. Regenxbio has made significant strides in advancing gene therapy treatments for various genetic disorders, including ophthalmic, metabolic, and neurodegenerative diseases. As an innovative and pioneering company, Regenxbio is committed to revolutionizing the future of gene therapies.

The main competitors of Regenxbio Inc in the market include other gene therapy companies such as bluebird bio, Sangamo Therapeutics, uniQure, and Spark Therapeutics.

Regenxbio Inc is primarily active in the biotechnology industry.

The business model of Regenxbio Inc is focused on developing and commercializing gene therapy treatments for various genetic diseases. Regenxbio utilizes its proprietary adeno-associated virus (AAV) gene delivery platform, which enables targeted and precise gene therapy delivery to specific cells in the body. This versatile platform allows Regenxbio to address a wide range of genetic disorders, including neurodegenerative diseases, metabolic disorders, and ophthalmic diseases. By leveraging their expertise in gene therapy and collaborating with partners, Regenxbio aims to bring effective and innovative treatments to patients with unmet medical needs.

Regenxbio hissesinin F/K oranı -1,76.

Regenxbio KUV 4,31 dir.

Regenxbio için AlleAktien Kalite Skoru 4/10'dur.

beklenen Regenxbio cirosu 97,38 Milyon. USD dir.

beklenen Regenxbio karı -238,61 Milyon. USD olarak gerçekleşmiştir.

Regenxbio Inc is a biopharmaceutical company focused on the development of gene therapies for rare genetic diseases. The company's business model is based on the discovery, development, and commercialization of innovative gene therapies to improve the lives of patients worldwide. Regenxbio was founded in 2009 and is headquartered in Rockville, Maryland (USA). As a pioneer in the field of gene therapy, the company has developed an extensive platform based on AAV vector technology. This platform allows Regenxbio to develop customized gene therapies and create new treatment options for patients with rare diseases. Regenxbio's research and development focuses on the identification and characterization of AAV vectors, each capable of transporting and expressing specific genes. Regenxbio has developed a wide range of AAV vectors tailored to the needs of patients with different conditions. The company has partnerships with numerous pharmaceutical and biotech companies such as Novartis, Alexion Pharmaceuticals, and Pfizer. These partnerships focus on the development of gene therapy solutions for various diseases such as cystic fibrosis, hemophilia, and Fabry disease. Regenxbio also has its own pipeline of gene therapy products in various stages of clinical development. Some of the products developed by Regenxbio include: - RGX-314: A gene therapy for the treatment of wet age-related macular degeneration (AMD). This therapy is based on the use of AAV8 vectors to transport the gene for the anti-VEGF antibody into the eye. - RGX-121: A gene therapy for the treatment of mucopolysaccharidosis type II (MPS II). This therapy is based on the use of AAV9 vectors to transport the gene for the enzyme iduronate-2-sulfatase (IDS) into the brain. - RGX-111: A gene therapy for the treatment of mucopolysaccharidosis type I (MPS I). This therapy is based on the use of AAV9 vectors to transport the gene for the enzyme alpha-L-iduronidase (IDUA) into the brain. - RGX-501: A gene therapy for the treatment of hemophilia A. This therapy is based on the use of AAV8 vectors to transport the gene for factor VIII into the liver. Regenxbio is on its way to becoming one of the leading companies in the gene therapy industry. The customized platform for gene therapy development, close collaboration with partners, and the company's own pipeline of gene therapy products should bring growth and success to the company in the future.

Regenxbio, yılda kez dağıtılmak üzere 0 USD tutarında temettü ödemektedir.

Regenxbio için şu an için temettü hesaplanamıyor veya şirket temettü dağıtmıyor.

Regenxbio şirketinin ISIN kodu US75901B1070’dir.

Regenxbio 'nin WKN'si A140E0 'dir.

Regenxbio için Ticker RGNX’dir.

Son 12 ay içerisinde Regenxbio, tutarında bir temettü ödedi. Bu, yaklaşık olarak oranında bir temettü verimine denk gelmektedir. Gelecek 12 ay için Regenxbio, tahmini olarak 0 USD tutarında bir temettü ödemesi yapacak.

Regenxbio şirketinin mevcut temettü verimi .

Regenxbio dönemsel olarak temettü ödemesi yapar. Bu ödemeler aylarında gerçekleştirilir.

Regenxbio, son 0 yıl içerisinde her yıl temettü ödedi.

Önümüzdeki 12 ay için 0 USD tutarında temettü ödenmesi beklenmektedir. Bu, 0 % oranında bir temettü verimidir.

Regenxbio, 'Sağlık' sektörüne atanmıştır.

Son Regenxbio tarihinde 0 USD tutarındaki en son temettüyü alabilmek için, hisseyi 20.11.2024 tarihindeki Ex-Tag'den önce portföyünde bulundurman gerekiyordu.

Son ödeme tarihi 20.11.2024 olarak gerçekleşti.

2023 yılında Regenxbio tarafından 0 USD olarak temettüler dağıtıldı.

Regenxbio hisselerinin temettüleri USD olarak dağıtılır.